Outcome MeasureOther

CGI-I

Clinical Global Impression – Improvement Scale

2 Papers in Blossom

Clinical Thresholds

17
Very much improved
Score 1–1
Much improved
Score 2–2
Minimally improved
Score 3–3
No change
Score 4–4
Minimally worse
Score 5–5
Much worse
Score 6–6
Very much worse
Score 7–7

Outcome Data Across Studies

Reported results for CGI-I across 1 study with quantitative data.

Outcome data across 4 study arm–timepoint observations
SD
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Ketamine 2x/week(experimental)29182.0——
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Placebo 2x/week(inactive)29164.0——
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Ketamine 3x/week(experimental)29172.0——
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Placebo 3x/week(inactive)29164.0——

Papers Using CGI-I

Open Accessindividual

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

This multicenter, double-blind, randomised, placebo-controlled study (n=67) investigated the antidepressant effects of ketamine (35mg/70kg) in relation to the dose frequency administered to patients with depression (TRD). Results indicated that both a twice-weekly and thrice-weekly administration regimen maintained antidepressant efficacy over 15 days.

Published
Journal
American Journal of Psychiatry
Authors
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., Kurian, B., Winokur, A., Fava, M., Manji, H., Drevets, W. C., Nueten, V.
Open Accessindividual

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

This rigorous randomised controlled trial (n=73) found that ketamine has rapid (24 hours) anti-depressant effects (MARDS) for those with treatment-resistant depression (TRD). Compared to the placebo group (midazolam), ketamine led to greater improvements in MADRS scores by 7.95 points and the response rate was greater in the ketamine group.

Published
Journal
American Journal of Psychiatry
Authors
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., Mathew, S. J.

Quick Facts

Full Name
Clinical Global Impression – Improvement Scale
Domain
Other
Papers Indexed
2
Score Range
1–7
Interpretation
Lower = better
Unit
points
Reference
Visit
All Measures